Faculty

Kiran Musunuru, MD, PhD, MPH, ML, MRA

Barry J. Gertz Professor for Translational Research

Department: Medicine

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Email:
kiranmusunuru@gmail.com

Education
AB (Biochemical Sciences)
Harvard College, Cambridge, MA, 1997.
PhD (Biomedical Sciences)
The Rockefeller University, New York, NY, 2003.
MD (Medicine)
Weill-Cornell Medical College, New York, NY, 2004.
MPH (Epidemiology)
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2009.
ML (Law)
University of Pennsylvania Law School, Philadelphia, PA, 2019.
MRA (Regulatory Affairs)
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2024.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Jiang AY, Cristian A, Brooks DL, Feierman ER, Chen PZ, Whittaker MN, Pierce SE, Sakai HA, Chen H, Liu D, Randolph PB, Li AH, Hsu A, Omo-Lamai SO, Tao YA, Owusu-Amo B, Wang X, Wang X, Musunuru K, Liu DR.: Efficient prime editing in vivo and in vitro using lipid nanoparticles. Nat Nanotechnol Jun 2026.

Gautier MK, King K, Han Y, Said H, Alameh MG, Wang X, Hong X, Musunuru K, Ahrens-Nicklas RC.: In vivo adenine base editing rescues brain biochemistry and improves motor deficits in a common phenylketonuria variant. Mol Ther Adv 34: 201760, May 2026.

Feierman ER, Whittaker MN, Quigley A, Brooks DL, McVeigh P, Nan AX, Hsu A, Said H, Soliman OY, Giovenco R, Davidson BL, Alameh MG, Liu DR, Wang X, Musunuru K, Ahrens-Nicklas RC.: Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform. Am J Hum Genet 113: 891-899, May 2026.

Ambardekar AV, Bhatt A, Hoekstra M, Kelly MA, Musunuru K, Natarajan P.: Gene editing therapy in cardiovascular disease: 2026 ACC scientific statement: a report of the American College of Cardiology. J Am Coll Cardiol Mar 2026.

Kahn E, Cannon P, Musunuru K.: ASGCT's 2025 breakthroughs in targeted in vivo gene editing: meeting summary and insights. Mol Ther 34: 1298-1300, Mar 2026.

McDermott-Roe C, Lv W, Shao Y, Hoshino A, Arany Z, Musunuru K.: CRISPR/Cas9 screens implicate RARA and SPNS1 in doxorubicin cardiotoxicity. JACC CardioOncol Page: 48-61, Feb 2026.

Schwab RD, Degaramo D, Hong SJ, Bi X, Faruqi A, Aguilar W, Brookens SK, Keane JT, Liu F, Musunuru K, Rader DJ, Posey AD Jr.: Chimeric antigen receptor regulatory T cells targeted against oxidized low-density lipoprotein reduce atherosclerotic plaque development. Circulation 153: 319-337, Feb 2026.

Musunuru K.: The dawn of interventional genetics. Am J Hum Genet 113: 1-2, Jan 2026.

Angelini Stewart A, Ahrens-Nicklas RC, Tsai SQ, Musunuru K, Giannikopoulos P, Clelland CD.: Measurement and clinical interpretation of CRISPR off-targets. Nat Genet Page: 20-27, Jan 2026.

Yu TW, Vitarello J, Musunuru K, Ahrens-Nicklas RC, Liu DR, Mellion ML, Urnov F, Yan W, Chunduru S, Barrett D, Flotte TR, Woodcock J.: Response to the FDA's proposed pathway for individualized genetic therapies. Mol Ther 34: 1-2, Jan 2026.